Thrivent Financial For Lutherans grew its holdings in shares of Mednax, Inc (NYSE:MD) by 5.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,730 shares of the company’s stock after buying an additional 970 shares during the quarter. Thrivent Financial For Lutherans’ holdings in Mednax were worth $1,131,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of MD. UBS Asset Management Americas Inc. grew its holdings in shares of Mednax by 5.8% during the first quarter. UBS Asset Management Americas Inc. now owns 322,027 shares of the company’s stock valued at $22,342,000 after buying an additional 17,635 shares during the last quarter. Parametric Portfolio Associates LLC lifted its position in shares of Mednax by 15.9% during the first quarter. Parametric Portfolio Associates LLC now owns 131,083 shares of the company’s stock valued at $9,095,000 after purchasing an additional 17,989 shares in the last quarter. Pacer Advisors Inc. lifted its position in shares of Mednax by 3.2% during the first quarter. Pacer Advisors Inc. now owns 1,795 shares of the company’s stock valued at $125,000 after purchasing an additional 55 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Mednax by 55.2% during the first quarter. JPMorgan Chase & Co. now owns 79,610 shares of the company’s stock valued at $5,524,000 after purchasing an additional 28,301 shares in the last quarter. Finally, KBC Group NV lifted its position in shares of Mednax by 79.6% during the first quarter. KBC Group NV now owns 13,382 shares of the company’s stock valued at $928,000 after purchasing an additional 5,931 shares in the last quarter.

Shares of Mednax, Inc (NYSE MD) opened at 43.57 on Friday. The company has a market capitalization of $4.02 billion, a price-to-earnings ratio of 13.88 and a beta of 0.37. The company’s 50-day moving average is $43.05 and its 200-day moving average is $54.25. Mednax, Inc has a 12-month low of $40.78 and a 12-month high of $72.13.

Mednax (NYSE:MD) last posted its earnings results on Friday, July 28th. The company reported $0.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.04. Mednax had a return on equity of 11.89% and a net margin of 8.78%. The company had revenue of $843.00 million for the quarter, compared to analyst estimates of $849.49 million. During the same quarter in the previous year, the firm earned $1.03 earnings per share. The firm’s quarterly revenue was up 9.2% compared to the same quarter last year. Analysts predict that Mednax, Inc will post $3.31 EPS for the current year.

Several analysts have commented on the stock. BidaskClub raised shares of Mednax from a “sell” rating to a “hold” rating in a research report on Friday, June 23rd. Robert W. Baird reaffirmed a “hold” rating and issued a $47.00 price objective on shares of Mednax in a research report on Sunday, September 3rd. Stephens raised shares of Mednax from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $55.00 to $68.00 in a research report on Thursday, June 22nd. Jefferies Group LLC reaffirmed a “hold” rating and issued a $53.00 price objective (up previously from $50.00) on shares of Mednax in a research report on Thursday, July 6th. Finally, KeyCorp upgraded shares of Mednax from a “sector weight” rating to an “overweight” rating and set a $51.00 target price for the company in a research note on Sunday, September 17th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $56.63.

In other Mednax news, insider John C. Pepia sold 3,000 shares of Mednax stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $42.85, for a total value of $128,550.00. Following the transaction, the insider now owns 35,569 shares in the company, valued at $1,524,131.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.40% of the stock is owned by insiders.

COPYRIGHT VIOLATION NOTICE: This report was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/10/06/thrivent-financial-for-lutherans-has-1-13-million-stake-in-mednax-inc-md.html.

Mednax Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mednax, Inc (NYSE:MD).

Institutional Ownership by Quarter for Mednax (NYSE:MD)

Receive News & Stock Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related stocks with our FREE daily email newsletter.